Olaparib + Abiraterone is FDA approved for mutated-BRCA prostate cancers. Olaparib has a bit of convoluted story to unpack in this patient population.

Have we finally found a way to minimize the peripheral neuropathy from paclitaxel.....with cilostazol?

PROpel: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2200043

Cilostazol RCT: https://doi.org/10.1002/phar.2830

Cilostazol effect on Schwann cells: https://doi.org/10.1016/j.neuropharm.2021.108514